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Missed Opportunities in HPV Vaccination 
 
Abstract (Word Count 244) 
 
Objective:  To use the 3 dose HPV vaccine administration (given at 0, 1-2 and 6 months) to 
quantify opportunities to improve efficacy in the delivery of preventive health services. 
Methods:  This was a retrospective, claims-based analysis using data provided by a single 
managed care plan.  Female patients aged 9-26 who were continuously enrolled between 2009 
through 2011 and received ≥ dose of the HPV vaccine during 2010 were analyzed.  The 
proportion of initiators who did and did not completed the vaccine series, the timing and location 
of doses, and the number of outpatient visits during which the vaccine could have been given to 
non-completers were determined. 
Results: 1,830 patients were analyzed in the 2010 sample.  843 (46%) were continuously 
enrolled during the three-year observation period.  500 (59%) completed 3 doses.  Among 
completers, the interval range between doses 1 and 2 was 27-619 days (median 96 days).  The 
interval range between doses 2 and 3 was 32-621 days (median 127 days).  261 (52%) 
completers received dose 2, and 139 (28%) received does 3 over 1 month late.  Among the 343 
non-completers, 137 (40%), and 206 (60%) completed 1 and 2 doses, respectively.  63% of 
single-dose recipients and 17% of 2-dose recipients had at least 1 visit within the eligible time 
period for administration.  
Conclusion:  Nearly half of HPV vaccine initiators do not complete the vaccine series.  Of those 
who do, a large percentage complete it late.  This example quantifies the potential for reminders, 




Level of Evidence: II 
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Introduction: Today in the U.S. about 50% of the recommended preventive health care is 
carried out1.  In this study, we examine experience with the administration of the HPV vaccine in 
order to address a more generalized problem of effective delivery of preventive health services. 
 The vaccines (2 are available) are given in a series of 3 shots over 6 months.  Both are currently 
approved for males and females aged 9 to 262,3.  Studies have shown that, among those who start 
the series, completion rates are about 50%4-8.   
  
This pilot study quantifies opportunities for improvement in vaccine completion rates.  We 
analyzed claims of a single health plan who received at least 1 dose of the HPV vaccine. We 
assess the potential impact of registries, reminders and outreach and consider what level it should 
be carried out, should it be at the level of the individual office, the health care delivery 
organization, the health plan, or the regional Department of Public Health?  How much 
redundancy in the system is healthy?   
 
Materials and Methods 
This is a retrospective, claims-based, observational study of patients enrolled in a single health 
plan during 2010.  All claims for female patients between the ages of 9 and 26 who had a claim 
for HPV vaccine in 2010 were obtained from the health plan.  Claims were based on CPT code 
of 90649: Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine 
(Gardasil, Merck) or 90650: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, 
Recombinant (CERVARIX, GlaxoSmithKline Biologicals).  Since the 6 month series could 
easily cross over into adjacent year (and the maximum interval for administration is listed as 1 
year by the manufacturer) we focused on the subgroup with continuous enrollment for 2009-11.  
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Collected data included year of birth, dates of vaccine administration, specialty of provider, 
provider group, continuous or sporadic enrollment for 2009, 2010, 2011, and, for those with 
fewer than 3 doses, interval visit dates and provider specialties and groups.   
 
We determined the number of doses for each participant, and the intervals between the doses.  
For those without 3 documented vaccine doses we analyzed evaluation and management (E&M) 
codes for office visits (CPT codes 992XX and 993XX) to determine whether or not these 
patients were seen during a dosing interval when they would have been eligible for completion 
of the vaccine course.  For those who had only 1 dose we looked for visits occurring between 60 
and 365 days after that dose.  For those receiving 2 doses, we looked for visits occurring between 
120 days after dose 2 and 365 days after dose 1.  The range in the number of visits and median 
number of visits among those with interval visits were calculated. We calculated visits that 
occurred with the same specialty and same group for those with eligible visits (specific provider 
identifiers were not made available for privacy reasons).   
 
Confidence intervals and p values for comparisons were calculated using STATA version 9 
(STATACorp LP, College Station, TX).  Percentages are rounded to the nearest 1%. 
 
The study was approved by the University of Massachusetts Medical Institutional Review Board 





The total number of female patients aged 9-26 for whom at least 1 HPV vaccine claim was 
submitted during 2010 was 1,830.  The median age was 16.  Of the total, 840 (46%) were 9 to 15 
years of age and 990 (54%) were 16 to 26 years of age in 2010.   843 (46%, 95% CI 44-48%) 
were continuously enrolled for all 3 years (Figure 1).  Among these, 49% were 9-15yo and 44% 
of those who were 16-26yo (p<0.05). 
 
Five hundred of the 843 (59%, 95% CI: 56-63%) who were continuously enrolled for 3 years 
completed the HPV vaccination series   Enrollees under 16 completed the series 66% of the time, 
while those 16 and over completed it 53% of the time (p<.05).  Among completers, the interval 
range between dose 1 and dose 2 was 27-619 days (median of 96 days).  The interval range 
between dose 2 and dose 3 was 32-621days (median of 127 days).  Among completers, 261 
(52%, 95% CI: 48-57%) received dose 2, and 139 (28%, 95% CI 24-32%) received dose 3 over 1 
month late.  (Table 1). 
 
Among the 343 enrollees who were continuously enrolled and did not complete the three-dose  
course, 137 received only 1 dose (40%, 95% CI: 35-45%) and 206 received 2 doses (60%, 95% 
CI: 55-65%).  Among these non-completers, , 223 (65%, 95% CI: 60-70%) did not have a visit 
with a provider in the year post dose.  Among non-completers with one dose, 86 of 137 (63%, 
95% CI: 54-71%) had a visit in the eligible interval, and 55 of the 137 (40%, 95% CI: 32-49%, 
median 2, range 1-21) had at least one visit with the same group and the same specialty.  Thirty-
four of 206 with 2 doses (17%, 95% CI: 12-22%) had a visit in an eligible interval and, of these, 
23 (11%) had at least 1 visit with the same group and same specialty (11%, 95% CI: 7-16%, 
median 2, range 1-7).  The range in number of eligible visits for those receiving 1 dose was 1-21 
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visits with a median of 2 (95% CI: 1-2) and for those receiving two doses the range was 1-7 with 
a median of 1 (95% CI: 1-2) (Figures 1 and 2).  By age group, older non-completers were more 
likely than younger ones to have had an interval visit within the time period they were eligible 
for vaccination: 41% vs 26% for those older than 15 and younger than 15, respectively (p < 
0.05).   
Comment: 
This study used completion rates for the HPV vaccine as a model to look for opportunities to 
improve care in a multi-step treatment plan that spans several months.  Clearly no one approach 
has the potential to markedly improve completion rates.  Movement of patients out of the health 
plan was common; 54% of those who received at least 1 dose not having continuous coverage 
during the observation period.  This limits the ability of plans to track and remind patients unless 
care data is exchanged among plans at enrollment.  This does, however,  point to a potential 
target for public health registries which can track individuals regardless of their insurance status..  
Failure to complete the vaccine course was common , even among those who were continuously 
enrolled in insurance and had no co-pays (41%),.  In 1/3 of the cases (36%) non-completers were 
seen at a provider’s office in interval time period in which vaccine administration would have 
been appropriate.  It is possible they did not receive the vaccine because in half of these cases, 
the enrollee was seen by a different provider than the one who had initially administered the 
vaccine.  These missed opportunities could be decreased by incorporating provider reminders at 
the point of service.  Such point of service reminders would, at most, improve compliance by 
36% and would require reminders at visits throughout the medical group, not just the initial 
provider’s office.  Finally, for the sixty-five percent of cases that were continuously enrolled but 
not seen in an appropriate interval, outreach at the level of plan, organization or office may be 
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effective.  An informal survey of the largest providers in this study revealed that none were 
conducting outreach for missed doses of this vaccine at the time of this study. 
 
Another issue relates to late dosing.  Although dose 2 should be given in the 1 to 2 month 
interval and dose 3 at about 4 months from dose 2, we found that late dosing was common.  
Among completers, late dosing occurred in 52% and 28% of those receiving dose 2 and 3, 
respectively.  One month was chosen to quantify lateness since it was felt that this was a 
reasonable interval to exclude those who may have simply had to reschedule a visit and identify 
those who may have needed outreach.   
Several studies have shown that patient outreach can be successful in increasing vaccine 
compliance.  While automated calls have not shown success, personal telephone calls, text 
messaging10-12, e-mails13, and letters14,15 have.  These have been tried both as reminders pre-
visit16 and outreach after missed visits.  Reminders to both the parent and the adolescent have 
been tried17.  All have been met with modest success with odds ratios of 1.1 to 218,19 .  Obtaining 
accurate patient contact information is challenging, especially in the adolescent population. 20. 
Results have been mixed with Stockwell, dealing with a lower socioeconomic population, 
realizing a less than 5% increase21 to an absolute increase of over 40% in attendance rates by 
Prasad11. 
 
Studies on the effectiveness of reminders at the point of service have shown mixed results22-25.  
This may relate to complex interfaces and high false alarm rates that lead to alerts being ignored.  
Nonetheless, some results have been very encouraging with Riley showing  a 40% absolute 




A certain level of redundancy will be desirable in maximizing response rates. With practices 
integrating, registries and reminders may be appropriate at the group level- with pop-ups 
occurring wherever the patient and group are in contact.  Further down the line, when statewide 
vaccination registries and regional Health Information Exchanges are functional, even broader 
opportunities will become available for tracking and outreach.  This is especially relevant for the 
patients who may change providers or plans.   
 
One strength of this study is the fact that all contacts with the health care system were obtained 
with claims data (it is unlikely that patients would opt to get the vaccine at ~$120/dose on their 
own) and it looked at continuously insured patients who had no co-pay for the vaccine 
administration.   
 
A weakness of this study was that the population of Central Massachusetts encompassed in this 
study is, by census, primarily Caucasian, with less than 20% Hispanic and less than 10% black.  
This does not mirror the population of other urban centers and, since health care behaviors may 
vary among these groups, different results may be expected elsewhere.  In addition, being a 
claims based study we were not able to determine how often failure to continue the vaccine 
course was intentional.  Although the numbers in this study are relatively small for a claims-
based analysis, they are well above the threshold for finding clinically significant observations. 
 
This study has shown that there are multiple opportunities to address missed and late vaccine 
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